X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, granted on August 30, 2024, consist of options to purchase 230,588 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.70 per share, equal to the closing price of X4's stock on the grant date. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and was approved by X4's Compensation Committee.
X4 Pharmaceuticals (Nasdaq: XFOR), un'azienda focalizzata sul miglioramento della vita delle persone affette da malattie rare del sistema immunitario, ha annunciato l'emissione di premi di incentivazione per nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria del 2019. I premi, concessi il 30 agosto 2024, consistono in opzioni per l'acquisto di 230.588 azioni dell'azione comune di X4. Queste opzioni hanno un termine di dieci anni e un prezzo di esercizio di 0,70 $ per azione, pari al prezzo di chiusura delle azioni di X4 alla data di emissione. Le opzioni matureranno in quattro anni, con il 25% che matura dopo 12 mesi e il restante che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego. Questa concessione è in linea con la Regola di Quotazione Nasdaq 5635(c)(4) ed è stata approvata dal Comitato di Compensazione di X4.
X4 Pharmaceuticals (Nasdaq: XFOR), una empresa centrada en mejorar la vida de las personas con enfermedades raras del sistema inmunológico, ha anunciado la emisión de premios de incentivo para nuevos empleados bajo su Plan de Incentivo de Capital de 2019. Los premios, otorgados el 30 de agosto de 2024, consisten en opciones para comprar 230,588 acciones de las acciones ordinarias de X4. Estas opciones tienen un plazo de diez años y un precio de ejercicio de $0.70 por acción, igual al precio de cierre de las acciones de X4 en la fecha de otorgamiento. Las opciones se consolidarán en un período de cuatro años, con el 25% consolidándose después de 12 meses y el resto consolidándose mensualmente durante los siguientes 36 meses, sujeta a la continuidad del empleo. Esta concesión está en línea con la Regla de Cotización Nasdaq 5635(c)(4) y fue aprobada por el Comité de Compensación de X4.
X4 제약회사(Nasdaq: XFOR)는 희귀 면역계 질환을 가진 사람들의 삶을 개선하는 데 집중하는 회사로, 2019년 유인 주식 보상 계획에 따라 새로운 직원에게 유인 보상을 발급했다고 발표했습니다. 2024년 8월 30일에 부여된 이 보상은 X4의 보통주 230,588주를 구매할 수 있는 옵션으로 구성되어 있습니다. 이 옵션의 유효 기간은 10년이며 주당 0.70 달러의 행사 가격을 지니고 있으며, 이는 부여일의 X4 주식 종가에 해당합니다. 이 옵션은 4년 동안 분할되어 발생하며, 12개월 후 25%가 발생하고 나머지는 다음 36개월 동안 매월 발생합니다. 이 보상은 계속 고용되는 조건입니다. 이 인센티브는 Nasdaq 상장 규칙 5635(c)(4)와 일치하며 X4의 보상 위원회에 의해 승인되었습니다.
X4 Pharmaceuticals (Nasdaq: XFOR), une société axée sur l'amélioration de la vie des personnes atteintes de maladies rares du système immunitaire, a annoncé l'émission de primes d'incitation pour de nouveaux employés dans le cadre de son Plan d'Incentives en Capital de 2019. Les primes, accordées le 30 août 2024, consistent en des options d'achat de 230 588 actions ordinaires de X4. Ces options ont une durée de dix ans et un prix d'exercice de 0,70 $ par action, égal au prix de clôture de l'action de X4 à la date d'octroi. Les options vont acquérir leurs droits sur quatre ans, avec 25% des droits acquérant après 12 mois et le reste acquis mensuellement au cours des 36 mois suivants, sous réserve de maintien de l'emploi. Cette attribution est conforme à la Règle de Cotation Nasdaq 5635(c)(4) et a été approuvée par le Comité de Rémunération de X4.
X4 Pharmaceuticals (Nasdaq: XFOR), ein Unternehmen, das sich darauf konzentriert, das Leben von Menschen mit seltenen Erkrankungen des Immunsystems zu verbessern, hat die Vergabe von Anreizprämien an neue Mitarbeiter im Rahmen seines Anreiz Aktienoptionsprogramms 2019 bekannt gegeben. Die am 30. August 2024 gewährten Prämien bestehen aus Optionen zum Kauf von 230.588 Aktien von X4s Stammaktien. Diese Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 0,70 $ pro Aktie, was dem Schlusskurs der X4-Aktie am Gewährungstag entspricht. Die Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach 12 Monaten und der Rest monatlich in den folgenden 36 Monaten fällig wird, vorbehaltlich der fortgesetzten Beschäftigung. Diese Gewährung entspricht der Nasdaq-Listing-Regel 5635(c)(4) und wurde vom Vergütungsausschuss von X4 genehmigt.
- Inducement grants may help attract and retain new talent
- Aligns employee interests with company performance through stock options
- Potential dilution of existing shareholders' equity
- Exercise price of $0.70 per share indicates low stock value
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 230,588 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares of X4 Pharmaceuticals (XFOR) were granted as inducement awards on August 30, 2024?
What is the exercise price for the stock options granted by X4 Pharmaceuticals (XFOR) on August 30, 2024?
What is the vesting schedule for the inducement stock options granted by X4 Pharmaceuticals (XFOR)?
Under which plan did X4 Pharmaceuticals (XFOR) issue the inducement awards announced on September 3, 2024?
